No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .
Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy
BACKGROUND There is accumulating evidence that inflammatory cytokines have an important role in the pathogenesis of heart failure . Plasma concentrations of tumour necrosis factor alpha ( TNF-alpha ) are high in heart failure and have been correlated with the severity of symptoms . Pentoxifylline suppresses the production of TNF-alpha . This study aim ed to assess the effects of pentoxifylline on left-ventricular function and functional class in patients with idiopathic dilated cardiomyopathy . METHODS We undertook a single-centre , prospect i ve , double-blind , r and omised , placebo-controlled trial , in which 28 patients with idiopathic dilated cardiomyopathy were assigned pentoxifylline 400 mg three times daily or matching placebo .  Clinical , echocardiographic , and radionuclide assessment s were done at baseline and after 6 months of treatment . Primary endpoints were New York Heart Association ( NYHA ) functional class and left-ventricular function . FINDINGS Baseline characteristics were similar in the two groups . Four patients  died during the study period , all in the placebo group . After 6 months of treatment , the proportion of patients in NYHA functional class I or II was higher in the pentoxifylline group than in the placebo group ( 14/14 vs 10/14 ; p=0.01 ) , and ejection fraction was higher in the pentoxifylline group than in the placebo group ( mean 38.7 % [ SD 15.0 ] vs 26.8 % [ 11.0 ] , p=0.04 ) . At 6 months , TNF-alpha plasma concentrations were significantly lower in the pentoxifylline-treated group than in the placebo group ( 2.1 [ 1.0 ] vs 6.5 [ 5.0 ] pg/mL , p=0.001 ) . INTERPRETATION Our results suggest that pentoxifylline improves symptoms and left-ventricular systolic function in patients with idiopathic dilated cardiomyopathy . These results must be confirmed in larger-scale trials
No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .